Publicaciones en colaboración con investigadores/as de Hospital Vall d'Hebron (46)

2024

  1. PTCy vs CNI–based GVHD prophylaxis in HLA-matched transplants for Hodgkin lymphoma: a study of the LWP of the EBMT

    Blood Advances, Vol. 8, Núm. 15, pp. 3985-3992

  2. Post-transplant cyclophosphamide compared to sirolimus/tacrolimus in reduced intensity conditioning transplants for patients with lymphoid malignancies

    Bone Marrow Transplantation, Vol. 59, Núm. 10, pp. 1369-1375

  3. Real-World Experience with Isavuconazole in Allogeneic Stem Cell Transplantation in Spain

    Transplantation and Cellular Therapy, Vol. 30, Núm. 10, pp. 1033.e1-1033.e8

  4. Torque Teno Virus plasma DNA load: a novel prognostic biomarker in CAR-T therapy

    Bone Marrow Transplantation, Vol. 59, Núm. 1, pp. 93-100

2023

  1. Assessment of the potential value of plasma Torque Teno virus DNA load monitoring to predict cytomegalovirus DNAemia in patients with hematological malignancies treated with small molecule inhibitors: A proof-of-concept study

    Journal of medical virology, Vol. 95, Núm. 7, pp. e28933

  2. Immunobiology of cytomegalovirus infection in patients with haematological malignancies undergoing treatment with small molecule inhibitors

    British Journal of Haematology, Vol. 200, Núm. 6, pp. e58-e61

  3. Quantifying the available capacity and resource needs for provision of CAR-T therapies in the National Health Service in Spain: a survey-based study

    BMJ open, Vol. 13, Núm. 7, pp. e071371

2021

  1. Clinical outcomes of allogeneic hematopoietic stem cell transplant recipients developing Cytomegalovirus DNAemia prior to engraftment

    Bone Marrow Transplantation, Vol. 56, Núm. 6, pp. 1281-1290

  2. Cytomegalovirus-specific T-cell immunity and DNAemia in patients with chronic lymphocytic leukaemia undergoing treatment with ibrutinib

    British Journal of Haematology

  3. Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma

    Cancer Medicine, Vol. 10, Núm. 10, pp. 3214-3223

  4. Thiotepa–busulfan–fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT

    Bone Marrow Transplantation, Vol. 56, Núm. 7, pp. 1593-1602

2020

  1. Executive summary of the consensus document of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), the Spanish Network for Research in Infectious Diseases (REIPI) and the Spanish Society of Haematology and Haemotherapy (SEHH) on the management of febrile neutropenia in patients with hematological malignancies

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 38, Núm. 4, pp. 174-181

  2. Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis

    Leukemia and Lymphoma, pp. 1-10

  3. Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Transplantation for Adults with Hematologic Malignancies

    Biology of Blood and Marrow Transplantation, Vol. 26, Núm. 2, pp. 358-366

  4. Risk factors and outcome of COVID-19 in patients with hematological malignancies

    Experimental Hematology and Oncology, Vol. 9, Núm. 1

  5. Use of micafungin as antifungal prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation (Allo-HSCT) in Spain (GETH-MIC)

    Revista Espanola de Quimioterapia, Vol. 33, Núm. 2, pp. 110-115

2019

  1. Author Correction: Donor lymphocyte infusions for B-cell malignancies relapse after T-cell replete allogeneic hematopoietic cell transplantation (Bone Marrow Transplantation, (2019), 54, 7, (1133-1137), 10.1038/s41409-018-0422-z)

    Bone Marrow Transplantation

  2. Donor lymphocyte infusions for B-cell malignancies relapse after T-cell replete allogeneic hematopoietic cell transplantation

    Bone Marrow Transplantation

  3. Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster after Autologous Stem Cell Transplantation: A Randomized Clinical Trial

    JAMA - Journal of the American Medical Association, Vol. 322, Núm. 2, pp. 123-133

  4. Effect of Sirolimus Exposure on the Need for Preemptive Antiviral Therapy for Cytomeglovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation

    Biology of Blood and Marrow Transplantation, Vol. 25, Núm. 5, pp. 1022-1030